<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04893603</url>
  </required_header>
  <id_info>
    <org_study_id>Silara201901</org_study_id>
    <nct_id>NCT04893603</nct_id>
  </id_info>
  <brief_title>To Evaluate Safety and Effectiveness of Transcatheter Aortic Valve System in Patients With Severe Aortic Stenosis</brief_title>
  <official_title>A Prospective, Multi-center, Single-arm Clinical Trial to Evaluate the Safety and Effectiveness of Transcatheter Aortic Valve System in Patients With Severe Aortic Stenosis With or Without Moderate or Lower Degree Regurgitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chengdu Silara Meditech Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chengdu Silara Meditech Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To Evaluate the Safety and Effectiveness of Transcatheter Aortic Valve System ( Chengdu&#xD;
      Silara Medtech Inc. ,Chengdu, China)in Patients with Severe Aortic Stenosis with or without&#xD;
      Moderate or Lower Degree Regurgitation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transcatheter Aortic Valve System (Chengdu Silara Medtech Inc. ,Chengdu, China) will be used&#xD;
      for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 16, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of All-cause Mortality</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of subjects who died from all causes in this population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Device Success</measure>
    <time_frame>Immediate post- procedure</time_frame>
    <description>Device Success is defined as a composite of :&#xD;
Absence of procedural mortality AND&#xD;
Successful vascular access, delivery and deployment of the device, and successful retrieval of the delivery system AND&#xD;
Correct positioning of prosthetic heart valve into the proper anatomical location AND&#xD;
Intended performance of the prosthetic heart valve (mean aortic valve gradient&lt;20 mmHg or peak velocity&lt;3 m/s, and no severe prosthetic valve regurgitation or PVL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Procedure Success</measure>
    <time_frame>Immediate post- procedure</time_frame>
    <description>Procedure Success is defined as no death, stroke, myocardial infarction and renal failure occurred within 72 hours after the operation on the basis of the final device success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delivery System Performance</measure>
    <time_frame>Immediate post- procedure</time_frame>
    <description>Delivery System Performance wil be evaluated subjectively by the researchers participating in the operation, which is generally classified as excellent, good ,average and poor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retrieval System Performance(if using)</measure>
    <time_frame>Immediate post- procedure</time_frame>
    <description>Retrieval System Performance wil be evaluated subjectively by the researchers participating in the operation, which is generally classified as excellent, good ,average and poor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exchange Systerm Evaluation</measure>
    <time_frame>Immediate post- procedure</time_frame>
    <description>Exchange Systerm Evaluation wil be evaluated subjectively by the researchers participating in the operation, which is generally classified as excellent, good ,average and poor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Valvular function evaluation, including valve stenosis, AR, valve function(e.g. EOA, gradient) and PVL</measure>
    <time_frame>Immediate post-procedure, 7days or discharge, 30 days, 6 months ,12months and 2-5 years</time_frame>
    <description>The evaluation criteria refer to the 2012 edition of the Association for Valvular Academic Research (VARC-2) consensus document</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Assessment</measure>
    <time_frame>30 days, 6 months,and 12 months</time_frame>
    <description>SF-12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA function</measure>
    <time_frame>7 days or discharge, 30 days, 6 months ,12 months and 2-5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of All-cause Mortality</measure>
    <time_frame>Immediate post- procedure ,7 days /discharge, 30 days, 6 months and 2-5 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Myocardial Infarction</measure>
    <time_frame>Immediate post- procedure, 7 days /discharge, 30 days, 6 months ,12months and 2-5 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of MACCE(including mortality, stroke, MI, re-procedure, Conduction disturbances and cardiac arrhythmias)</measure>
    <time_frame>Immediate post- procedure, 7 days /discharge, 30 days, 6 months,12months and 2-5 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Bleeding (life-threatening or disabling and major)</measure>
    <time_frame>Immediate post- procedure, 7 days /discharge, 30 days, 6 months,12months and 2-5 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Stroke</measure>
    <time_frame>7 days /discharge, 30 days, 6 months, 12 months and 2-5 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AKI (stage 2 and 3,or renal replacement therapy (RRT: Hemodialysis, abdomen Cavity dialysis, hemofiltration))</measure>
    <time_frame>7 days /discharge, 30 days, 6 months, 12 months and 2-5 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Permanent Pacemaker Implantation</measure>
    <time_frame>7 days /discharge, 30 days, 6 months, 12 months and 2-5 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of major vascular complications</measure>
    <time_frame>Immediate post- procedure, 7 days /discharge, 30 days, 6 months, 12 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Conduction disturbances and cardiac arrhythmias</measure>
    <time_frame>Immediate post- procedure, 7 days /discharge, 30 days, 6 months, 12 month and 2-5years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Other TAVI-related Complications</measure>
    <time_frame>Immediate post- procedure, 7 days /discharge, 30 days, 6 months, 12 month and 2-5years</time_frame>
    <description>including transfer to surgery , Accidental heart-lung machine, coronary obstruction, ventricular septal rupture, Mitral valve damage or dysfunction，cardiac tamponade，endocarditis ，valvular thrombus，Valve migration(shifting, detachment,embolism,error deployment）,valve in valve</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Severe Aortic Valve Stenosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with Transcatheter Aortic Valve Systerm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter Aortic Valve System</intervention_name>
    <description>Procedure: Transcatheter aortic valve replacement</description>
    <arm_group_label>Severe Aortic Valve Stenosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥70 years old;&#xD;
&#xD;
          2. Symptomatic severe aortic stenosis determined by echocardiogram, defined as: mean&#xD;
             gradient ≥40 mmHg or peak jet velocity ≥4.0 m/s, or an aortic valve area &lt;0.8 cm2 or&#xD;
             aortic valve area index &lt;0.5 cm2/m2.&#xD;
&#xD;
          3. NYHA Functional Class ≥II;&#xD;
&#xD;
          4. Life expectancy after aortic valve implantation thought to be &gt;1 year;&#xD;
&#xD;
          5. Native valvular or peripheral vascular anatomy is appropriate for TAVR;&#xD;
&#xD;
          6. Patient is assessed by at least two cardiothoracic surgeons and recorded as not&#xD;
             suitable for surgery;&#xD;
&#xD;
          7. Patient can understand the purpose of the study, voluntarily participates and signs&#xD;
             the informed consent form and is willing to accept the relevant examination and&#xD;
             clinical follow-up visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Anatomy is not appropriate for percutaneous valve implantation. Native valve annulus&#xD;
             diameter is not in the scope of application(native TAV diameter ≤21mm, or ≥30mm);&#xD;
&#xD;
          2. Evidence of an acute myocardial infarction within 30 days prior to the study&#xD;
             procedure, defined as: Q-wave myocardial infarction, or non-Q-wave myocardial&#xD;
             infarction, with CK-MB≥2 ULN/or elevated TN (WHO definition);&#xD;
&#xD;
          3. Any treatment for traumatic cardiac surgery within 30 day prior to the study&#xD;
             procedure(except coronary revascularization);&#xD;
&#xD;
          4. Pre-existing prosthetic valve in any position(except severely dysfunctional aortic&#xD;
             bioprosthesis), or severe (&gt;3+) mitral insufficiency, or Gorlin syndrome;&#xD;
&#xD;
          5. Hematological abnormality, defined as: Leukopenia (WBC &lt;3x10^9/L), acute anemia (Hb&#xD;
             &lt;90g/L), or thrombocytopenia (platelet count&lt;50×109/L),history of bleeding diathesis&#xD;
             or coagulopathy;&#xD;
&#xD;
          6. Hemodynamic unstable requiring myocardial contractile support or mechanical cardiac&#xD;
             assistance;&#xD;
&#xD;
          7. Severe ventricular insufficiency. Left ventricular ejection fraction (LVEF) &lt;20%;&#xD;
&#xD;
          8. Echocardiographic evidence of intra-cardiac thrombus or vegetation etc.;&#xD;
&#xD;
          9. Active pepticulcer or upper GI bleeding within 3 months prior to the study procedure;&#xD;
&#xD;
         10. Cerebral Vascular Accident (CVA) within 3 months prior to the study procedure,&#xD;
             including TIA;&#xD;
&#xD;
         11. A known hypersensitivity or contraindication to aspirin, heparin, ticlopidine or&#xD;
             clopidogrel, or sensitivity to contrast media, which cannot be adequately&#xD;
             pre-medicated;&#xD;
&#xD;
         12. Patients with infective endocarditis or other active stage of infection;&#xD;
&#xD;
         13. Currently participating in an investigational drug or another device trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongjian Wu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fuwai Hospital, CAMS&amp;PUMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Moyang Wang</last_name>
    <phone>(86)-010-68314466</phone>
    <email>wangmoyang1983@vip.sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fuwai Hospital, CAMS&amp;PUMC</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongjian Wu</last_name>
    </contact>
    <investigator>
      <last_name>Runlin Gao</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yongjian Wu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2021</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

